NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Trial Profile

NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs Aldoxorubicin (Primary) ; ALT 803 (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; CST 101 (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantKwest
  • Most Recent Events

    • 17 Jan 2018 According to a CytRx Corporation media release, firs patient has been dosed in the phase Ib portion if the trial.
    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top